Keytruda QLEX 165mg/2000units/ml injection 1vial x 4.8ml (pembrolizumab and berahyaluronidase alfa-pmph)

Reference priceEUR €577.50Original source price: INR 52,500.00. Converted estimates are available by currency selection.

Brand	Keytruda QLEX
Manufacturer	MSD Sharp & Dohme GmbH
Prescription required	Yes

Description

Keytruda QLEX 165mg/2000units/ml injection 1vial x 4.8ml(/) (pembrolizumab and berahyaluronidase alfa-pmph) is a medicine catalog record in the MediPriceHub database. Active ingredient: pembrolizumab and berahyaluronidase alfa-pmph. Clinical use summary: See the Benefits field on this page for the product-specific indication or intended use. That field is kept separate from catalog metadata so users can distinguish clinical information from packaging information. Manufacturer or supplier: MSD Sharp & Dohme GmbH. Therapeutic category: Medicine Library > Oncology Medicines > Head and Neck Cell Carcinoma. Pack information: 790 / 9600 4.8 (165 / 2000 / ). Origin country or market: United States. This page is for medicine catalog reference only and should be read together with the approved prescribing information in the patient or buyer's country.

Benefits

KEYTRUDA QLEX is a combination of pembrolizumab, a programmed death receptor-1 (PD-1)-blocking antibody, and berahyaluronidase alfa, an endoglycosidase, indicated: Melanoma Non-Small Cell Lung Cancer (NSCLC) Malignant Pleural Mesothelioma (MPM) Head and Neck Squamous Cell Cancer (HNSCC) Urothelial Cancer Microsatellite Instability-High or Mismatch Repair Deficient Cancer Microsatellite Instability-High or Mismatch Repair Deficient Colorectal Cancer (CRC) Gastric Cancer Esophageal Cancer Cervical Cancer Hepatocellular Carcinoma (HCC) Biliary Tract Cancer (BTC) Merkel Cell Carcinoma (MCC) Renal Cell Carcinoma (RCC) Endometrial Carcinoma Tumor Mutational Burden-High (TMB-H) Cancer Cutaneous Squamous Cell Carcinoma (cSCC) Triple-Negative Breast Cancer (TNBC) Ovarian Cancer 1 This indication is approved under accelerated approval based on tumor response rate and durability of response. Continued approval for this indication may be contingent upon verification and description of clinical benefit in the confirmatory trials. for the treatment of adult patients with unresectable or metastatic melanoma. for the adjuvant treatment of adult and pediatric patients 12 years and older with Stage IIB, IIC, or III melanoma following complete resection. in combination with pemetrexed and platinum chemotherapy, as first-line treatment of adult patients with metastatic nonsquamous NSCLC, with no EGFR or ALK genomic tumor aberrations. in combination with carboplatin and either paclitaxel or paclitaxel protein-bound, as first-line treatment of adult patients with metastatic squamous NSCLC. as a single agent for the first-line treatment of adult patients with NSCLC expressing PD-L1 [Tumor Proportion Score (TPS) ≥1%] as determined by an FDA-authorized test, with no EGFR or ALK genomic tumor ab

How to Use

Use pembrolizumab and berahyaluronidase alfa-pmph under the supervision of a qualified healthcare professional. It should be prepared and administered only by trained healthcare professionals in a setting appropriate for injectable or infusion medicines. Do not start, stop, change the dose, split or crush a dosage form, mix with other medicines, or repeat a course unless the approved product information or a clinician confirms that it is appropriate. Check the local prescribing information for age limits, dose adjustments, missed-dose instructions, storage after opening or reconstitution, and monitoring requirements.

Specification

Active ingredient: pembrolizumab and berahyaluronidase alfa-pmph. Pack size: 790 / 9600 4.8 (165 / 2000 / ). Pack unit: bottle. Manufacturer: MSD Sharp & Dohme GmbH. Origin country: United States. Source category: Medicine Library > Oncology Medicines > Head and Neck Cell Carcinoma. Availability, prescription status, storage, and exact approved use may vary by country. Check the local product information before clinical or procurement decisions.

Side Effects

The available source record does not provide a clean, product-specific adverse-reaction list. Potential risks depend on the active ingredient, dose, route, treatment duration, and patient condition. Check the approved local prescribing information for the complete adverse-reaction profile, warnings, contraindications, and monitoring requirements. Seek urgent medical care for severe allergic symptoms, breathing difficulty, fainting, severe skin reactions, chest pain, serious bleeding, or rapidly worsening symptoms.

Ces informations sont fournies à titre indicatif. Demandez conseil à un professionnel de santé avant d'utiliser un médicament.